Buformin
Based on 3 publication(s) in Google Scholar
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 692-13-7
- 화학식: C6H15N5
- 분자량:157.22
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
-
HY-12357
Bempedoic acidACL Inhibitor/AMPK Activator -
HY-111363
MK8722AMPK Activator -
HY-100548
GSK621AMPK Activator -
HY-112233
O-304AMPK Activator -
HY-B2099A
Buformin hydrochlorideAntidiabetic Agent -
HY-136447
ASP4132AMPK Activator -
HY-136093A
Lixumistat acetateAMPK Activator/Oxphos Inhibitor -
HY-13418A
DorsomorphinAMPK Inhibitor -
HY-50662
A-769662AMPK Activator -
HY-13418
Dorsomorphin dihydrochlorideAMPK Inhibitor -
![[6]-Gingerol](https://file.medchemexpress.com/product_pic/hy-14615.gif)
HY-14615
[6]-GingerolApoptosis Inducer -
HY-112769
EX229AMPK Activator
Publications Citing Use of MedChemExpress (MCE) Buformin
MoreAll AMPK Isoforms
More
Biological Activity
제품 설명
In Vitro
Buformin (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively[1].Buformin (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells[1].Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM
-
Incubation Time:5 days
-
Result:Reduced cell viability in erbB-2-overexpressing breast cells.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0.5 mM; 1 mM; 3 mM
-
Incubation Time:48 hours
-
Result:Increased cells arresting in G0/G1 phase.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM
-
Incubation Time:24 hours
-
Result:Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female MMTV-erbB-2 transgenic mice[1]
-
Dosage:7.6 mmol/kg
-
Administration:Oral administation; 7 days
-
Result:Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.
Chemical Information
-
CAS No. 692-13-7
-
분자량 157.22
-
화학식 C6H15N5
-
SMILES
NC(NC(NCCCC)=N)=N
-
Synonyms
1-Butylbiguanide
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Clin Sci
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway. [Abstract]2022 Feb 25;136(4):273-289. PMID: 35132999 -
Mol Metab
Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice. [Abstract]2024 Jan:79:101860. PMID: 38142972 -
순도&문서
References
[1]. Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res [Content Brief]
[2]. Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Buformin Related Classifications
HY-B2099 Related Classifications
Powered by Bioz